Noopept
| Tên sản phẩm | Noopept |
| Các tên gọi khác | GVS-111; N-Phenylacetyl-L-prolylglycine ethyl ester |
| Số CAS | 157115-85-0 |
| Công thức phân tử | C₁₇H₂₂N₂O₄ |
| Trọng lượng phân tử | 334.37 g/mol |
| Hình thức | Bột tinh thể màu trắng đến trắng ngà |
| Phương pháp phân tích (HPLC) | ≥ 99,01 TP3T |
| Điểm nóng chảy | 95–98°C |
| Mất mát khi sấy khô | ≤ 0,5% |
| Hàm lượng tro sau khi đốt | ≤ 0,1% |
| Kim loại nặng | ≤ 10 ppm |
Cần trợ giúp? Liên hệ với đội ngũ của chúng tôi
Noopept (developmental code GVS-111) is a dipeptide nootropic compound developed in Russia in the 1990s as a novel cognitive enhancer with neuroprotective properties. Structurally, it is a cycloprolyl-glycine derivative that shares some pharmacological similarities with racetams (particularly piracetam), but with significantly higher potency—estimated to be approximately 1,000 times more potent than piracetam.
Key : Unlike most nootropics that require weeks to show effects, Noopept has demonstrated rapid onset in research models. It exhibits both cognitive-enhancing và neuroprotective properties, including protection against oxidative stress, excitotoxicity, and ischemia-reperfusion injury. Noopept also increases brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) levels in the hippocampus.
Noopept exerts its effects through multiple pathways, distinguishing it from classic racetams:
| Lộ trình | Cơ chế | Research Finding |
|---|---|---|
| BDNF/NGF upregulation | Increases brain-derived neurotrophic factor and nerve growth factor in hippocampus | Supports synaptic plasticity, neurogenesis |
| AMPA/kainate receptor modulation | Positive allosteric modulation (similar to racetams) | Enhances glutamatergic transmission |
| Bảo vệ thần kinh | Reduces oxidative stress, inhibits lipid peroxidation, protects against excitotoxicity | Preclinical models of ischemia, traumatic brain injury |
| Cholinergic system | May enhance acetylcholine release (indirect) | Memory and learning support |
| Chống viêm | Reduces neuroinflammation (preclinical) | Bảo vệ thần kinh |
Noopept has been shown to protect against neurodegeneration in animal models of Alzheimer’s disease, Parkinson’s disease, and cerebral ischemia. It reduces amyloid-β toxicity and may have disease-modifying potential (preclinical only).
Công ty TNHH LyvBio. is a GMP-certified supplier of high-purity Noopept (GVS-111) for research and development applications.
Năng lực cung ứng:
Phương pháp phân tích (HPLC): ≥99.0%
Biểu mẫu: Crystalline powder
Công suất hàng tháng: Hơn 20 kg
Số lượng lớn: 1g – 10kg
Thời gian thực hiện: 3-5 business days (stock items)
Tài liệu: COA, MSDS, HNMR , HPLC chromatogram, stability data
Đảm bảo chất lượng:
HPLC purity with UV detection
Residual solvents tested (meets USP <467>)
Heavy metals tested (ICP-MS)
Structural confirmation (NMR upon request)
📧 Liên hệ: info@lyvbio.com
| Tham số | Thông số kỹ thuật | Phương pháp thử nghiệm |
|---|---|---|
| Phương pháp phân tích (HPLC) | ≥ 99,01 TP3T | HPLC-UV (210 nm) |
| Hình thức | Bột tinh thể màu trắng đến trắng ngà | Hình ảnh |
| Xác định | Thời gian lưu trên HPLC, NMR (theo yêu cầu) | HPLC / NMR |
| Điểm nóng chảy | 95–98°C | USP |
| Mất mát khi sấy khô | ≤ 0,5% | USP |
| Hàm lượng tro sau khi đốt | ≤ 0,1% | USP |
| Kim loại nặng | Pb ≤ 10 ppm; As ≤ 2 ppm; Cd ≤ 1 ppm; Hg ≤ 0.1 ppm | ICP-MS |
| Các chất liên quan | Tạp chất đơn lẻ ≤ 0,5%; Tổng ≤ 1,0% | HPLC-UV |
| Chất dung môi còn lại | Giới thiệu tiêu chuẩn USP | GC |
| Kích thước hạt | 95% through 80 mesh | Sieve Analysis |
Q: Is Noopept the same as Piracetam?
A: No. Noopept is a dipeptide derivative with different chemical structure, significantly higher potency (~1,000x), and distinct mechanisms (including BDNF/NGF upregulation). It is not a racetam, though it shares some pharmacological similarities.
Q: Is Noopept FDA-approved?
A: Không. Noopept is not FDA-approved for medical use in the United States. It is available as a research chemical for laboratory use only. It has been used as a prescription medication in Russia.
Q: What is the difference between Noopept and other nootropics?
A: Noopept is unique in its ability to upregulate BDNF and NGF in the hippocampus—a property not shared by classic racetams. It is also significantly more potent (microgram vs. milligram dosing).
Q: What is the primary active metabolite of Noopept?
A: Cycloprolylglycine (CPG). Noopept is rapidly metabolized to CPG, which is believed to contribute significantly to its pharmacological effects.
Q: Does Noopept have neuroprotective properties?
A: Yes. Preclinical studies have demonstrated neuroprotective effects in models of stroke, traumatic brain injury, excitotoxicity, and neurodegeneration (Alzheimer’s, Parkinson’s models).
Q: What is the effective dose range in animal studies?
A: Published studies report cognitive-enhancing and neuroprotective effects at 0.1–1 mg/kg (oral) in rodents—approximately 1,000 times more potent than piracetam.
Q: Are there human clinical trials for Noopept?
A: Limited human studies have been conducted in Russia, where Noopept is approved as a prescription nootropic.
Liên hệ: info@lyvbio.com
Room,5-0203, Unit 5, Beiyuanmen Street,Xi'an,Shaanxi,China
English English 
Russian
French
Korean
German
Polish
Japanese
Spanish
Italian
Vietnamese